Views & Analysis | Perspectives on pharma industry issues

Oncology

pharmaphorum podcast Episode 282 at ESMO26: Dr Chuck Link, Syncromune

ESMO26: Lowering toxicity, extending lives, with Syncromune

As the ESMO26 Congress commences in Madrid, pharmaphorum invited Syncromune Executive Chairman Dr Chuck Link onto the podcast.

Oncology

Why precision biomarkers will change the future of breast ca...

Blood-based biomarkers can provide an earlier, dynamic view of what is happening inside a patient, creating an opportunity to detect changes sooner.

Sales & Marketing

Benefits of marketing with AI tools, upward trajectory graph

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Oncology

Sponsored

12 Questions with Julia Jakl

Learn more about Julia Jakl, VP and Business Unit Head, Oncology UK at GSK, in a new 12 Questions With.

Market Access

Sponsored

The pre-commercial case for connecting data before acquiring...

For EBPs, launch requires a data strategy that starts with agreement on the KPIs, and those depend on the therapeutic areas.

Articles

Summary of day one of the European Meeting of ISMPP: “Doing ...

As our medical communications month draws to a close, Ryan Woodrow of Aspire Scientific shares an overview of day one of the European Meeting of ISMPP. An overview of day two will follow shortly. It is essential that medical publication professionals follow guidelines and best practice to ensure that the industry’s reputation...

Articles

Improvements in quality and bioequivalence policies in Latin...

Dr Timothy Riley discusses how the commercial opportunities in the emerging market of Latin America are affected by pressures on lowering healthcare costs and tougher regulations. Latin America countries are viewed by much of the pharmaceutical industry as an emerging market that offers...

Articles

Orphan drug repositioning – to or from a more common disease...

In our rare disease focus month, Caroline Mathie looks at whether it is more beneficial for pharma to reposition a drug from a common disease to a rare disease, or vice versa. Finding new uses for known drug compounds is a strategy well recognised by the industry for both...

Sales & Marketing

Ending rational disengagement: Bridging the strategy-reality...

Organisations must secure strategic buy-in, embed platforms in existing workflows, and provide reps with actionable physician-ready hypotheses.

Sales & Marketing

Building a social presence inside regulatory guardrails

In the UK, promoting prescription-only medicines to the public is prohibited by law and by the ABPI Code - social media reactions and shares included.

Digital

Sponsored

Why AI transformation is really about people

Jeff Kaminski, global head of AI and data at Axtria and a former industry analyst, discusses culture, governance, and leadership challenges around AI.

Digital